- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About PMV Pharmaceuticals
PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations. It’s lead product candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. It is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function. Its second program, R273H, targets the p53 R273H hotspot mutation.
13.35%
1.42%
Stock Analysis
last close
$13.72
1-mo return
-19.8%
3-mo return
-10.6%
avg daily vol.
1.04M
52-week high
37.32
52-week low
11.44
market cap.
$597M
forward pe
-
annual div.
-
roe
-20.2%
ltg forecast
-
dividend yield
-
annual rev.
$--
inst own.
-
